Navin Fluorine International Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Broad-based 47% YoY revenue surge: All three segments delivered strong growth, with Specialty Chemicals and CDMO each up ~60% YoY, while HPP grew 35% on constructive pricing and volumes.
• Margins hit a new plateau: EBITDA margins expanded over 1,000 bps to 32%, and management now guides to a 30% annualized run-rate, plus/minus 200 bps, as operating leverage and efficiency gains compound.
• The CAPEX cycle is delivering on time: The AHF plant and cGMP-4 Phase-1 were both commissioned and began commercial supplies this quarter, converting announced projects into revenue-generating assets.
• The CDMO story is inflecting: Validation completed and commercial supplies commenced for the first European major from cGMP-4, with the dedicated plant expected to reach full utilization within the coming year.
• What to watch next quarter: The pace of Nectar ramp-up toward the targeted half-capacity utilization, the Chemours project completion in Q1 FY27, and any concrete updates on the advanced materials and electronic-grade CAPEX timelines.

Segment Performance

All three verticals delivered strong YoY growth, with the quarter's performance described as being in line with announced CAPEX plans rather than accidental.

• Specialty Chemicals sequential build: The ₹120-130 crore sequential growth came from a combination of the Nectar campaign conclusion and other pipeline products with scale-up orders. The agchem pipeline of one or two new molecules per quarter is starting to yield results.
• CDMO portfolio balance: The molecule pipeline carries a roughly 50-50 split between early/late-stage and commercial molecules, with more than one molecule expected to have a readout in the coming year.
• Agchem outlook improving: The sector has gone through rough weather over the last two years; next year seems to have a volume uptick expected by industry participants, though pricing pressure will persist.
• R-32 utilization: Running at 100% capacity; took a planned shutdown for catalyst changeover at Agro 1. Export realizations are better than domestic ones.

Ganatra: "We were possibly an early recognizers to that trend where we started to change the way we looked at our customers driving a portfolio-based conversation, focusing more on driving process improvements, etc., and therefore, becoming a long-term solution provider to our customers rather than just a mere supply chain contractor."

Margins & Operating Leverage

• EBITDA margin expansion: Margins improved to 34.5% driven by improved realization and operating efficiencies. Manufacturing excellence is the #1 priority, driving economies, removing inefficiencies, better processes, higher yields, and lower losses.
• Operating leverage in action: Earnings growth rate is surpassing revenue growth rate, resulting in operating leverage. Consolidated gross margins remained stable despite higher specialty chemicals salience because margins improved in both CDMO and HPP, while specialty remained largely flat.
• Staff cost containment: Nine-month staff cost has been largely flattish due to optimization. Going forward, employee costs should be contained at 7%-8% of revenue, though capability enhancement hires will continue.
• Subsidiary margin structure: NFASL does not have the same overhead structure as listed NFIL; proper transfer pricing arms-length association exists between entities. An analyst noted subsidiary EBITDA margins appeared to surge, but management declined to confirm a specific 65% incremental margin figure while agreeing directionally that margins are looking better.

Ganatra: "It is a product mix play, man. So that will continue to be unfortunately the reality."

CAPEX Projects: Delivery & Pipeline

Wave-1 projects concluded on time: AHF and cGMP-4 were both commissioned during the quarter, with commercial supplies already started.

• AHF as strategic capacity: Management frames the AHF plant as a "license to dream" — without it, the company could not have accessed the R-32 opportunity. The strategy is to consume AHF captively more and more, channeling it into niche chemistries and advanced plays to increase realization per kg.
• Nectar ramp-up: On track to utilize half the capacity this year; working to secure the other half or close to it.
• Advanced materials incubation: Initial evaluations underway for projects in the electronic chemical value chain. The company is baking CAPEX to access electronic grade, which is why the Bush Technology plant timeline is taking some time.
• Chemours revenue ramp: Initial capacity will drive accelerated adoption; management expects the project to come into fruition two years once it starts, with larger CAPEX discussions to follow at that stage. Specific revenue or quantity projections were declined due to confidentiality.

Ganatra: "We want to bake this CAPEX in a manner that we are able to access electronic grade. So, that is why it is taking some time, but hopefully not too long."

CDMO Inflection

• European major milestone: The MSA with the first EU major has a molecule continuously seeing product extensions and expansions. The dedicated plant should be fully utilized in the coming year itself. The final product is accessing newer geographies with approvals, including China as recently as a week ago.
• Revenue visibility: The engagement provides strong revenue visibility over the next three years. The company is inching closer to the aspirational CDMO number of ₹10 crore (10 crore).
• Readout catalysts: More than one molecule is expected to have a readout coming in the year, with good potential to access growth.
• Second EU major: Management did not directly address questions about the second EU major's contribution to the aspirational CDMO target, instead discussing the balanced portfolio and readouts generally.

AHF Downstream & New Age Industries

• Targeting new age industries: The company is targeting semiconductor manufacturing, data centers, and other new age industries across the world including India. Several projects with a wide range of largely global customers are at different stages.
• BF-3 for semiconductors: Part of the downstream equation; the company will play on its fluorination strengths and get into downstream higher purity gases including BF-3.
• Electronic grade strategy: The company will get to electronic grade but does not exclude solar applications. CAPEX is being designed to access electronic grade specifications.
• Customer validation: Management declined to specify how many customers have been validated or whether they are Indian or external, citing commercial sensitivity, only describing them as "downstream fluorinated chemistries" and "niche players."

Ganatra: "Think of it this way, Jason, we would not have been able to do or access R-32 opportunity if we did not have the AHF."

Guidance & Commitments

Key Metrics